These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 19783140

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
    Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk DI, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM.
    Biochemistry; 2004 Feb 24; 43(7):1928-38. PubMed ID: 14967033
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
    Tintori C, Selvaraj M, Badia R, Clotet B, Esté JA, Botta M.
    ChemMedChem; 2013 Mar 24; 8(3):475-83. PubMed ID: 23404750
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigm.
    Hurevich M, Swed A, Joubran S, Cohen S, Freeman NS, Britan-Rosich E, Briant-Longuet L, Bardy M, Devaux C, Kotler M, Hoffman A, Gilon C.
    Bioorg Med Chem; 2010 Aug 01; 18(15):5754-61. PubMed ID: 20619663
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
    Hamza A, Zhan CG.
    J Phys Chem B; 2006 Feb 16; 110(6):2910-7. PubMed ID: 16471901
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A synthetic heparan sulfate-mimetic peptide conjugated to a mini CD4 displays very high anti- HIV-1 activity independently of coreceptor usage.
    Connell BJ, Baleux F, Coic YM, Clayette P, Bonnaffé D, Lortat-Jacob H.
    Chem Biol; 2012 Jan 27; 19(1):131-9. PubMed ID: 22284360
    [Abstract] [Full Text] [Related]

  • 17. Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation.
    Kalyanaraman VS, Rausch DM, Osborne J, Padgett M, Hwang KM, Lifson JD, Eiden LE.
    J Immunol; 1990 Dec 15; 145(12):4072-8. PubMed ID: 1701782
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A combination of molecular dynamics and docking calculations to explore the binding mode of ADS-J1, a polyanionic compound endowed with anti-HIV-1 activity.
    Manetti F, Tintori C, Armand-Ugón M, Clotet-Codina I, Massa S, Ragno R, Esté JA, Botta M.
    J Chem Inf Model; 2006 Dec 15; 46(3):1344-51. PubMed ID: 16711753
    [Abstract] [Full Text] [Related]

  • 20. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors.
    Teixeira C, Serradji N, Maurel F, Barbault F.
    Eur J Med Chem; 2009 Sep 15; 44(9):3524-32. PubMed ID: 19410340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.